Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
about
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathologyObesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia.The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive functionClinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice.Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease.What amyloid ligands can tell us about molecular polymorphism and disease.Cerebral amyloid PET imaging in Alzheimer's disease.The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.Molecular and cellular pathophysiology of preclinical Alzheimer's disease.Amyloid Imaging: Poised for Integration into Medical Practice.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Is Alzheimer's disease a homogeneous disease entity?Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review.
P2860
Q33806930-A510266F-7711-40C0-904A-AF9513B00B03Q34345159-AF2F7852-1052-464E-A315-105677066F96Q34500210-9958C4EC-A173-44EE-91ED-FD955E4C9815Q34674417-7A06263E-5684-460A-8700-BDD45C74F926Q35529715-59DA2DB1-62D4-4FF6-B86D-941730FE8833Q36051462-ADAE9745-1B34-41E5-8D76-2DFB66553B8CQ36821001-AE07DE8E-DCE6-4FA6-90B1-18F796BBDD16Q36871202-266AE1CC-8D63-4459-84CF-598F3787FA66Q37459083-3483E21D-9839-4E28-B0F2-05609E44FA17Q38400601-D1919FA7-C708-4582-8B6A-370C2CB989EAQ38836004-CA1B0A4A-B36B-42B7-852A-41B219D3D443Q38939875-422E9B69-7BEE-4DAC-B15B-27E60B1E4883Q38979999-EA1BD9FD-E959-404D-BCB7-8F3835456274Q42251603-69B42456-1747-4CAB-85D0-A3AC932F6AECQ47759823-D019A92A-6357-485F-8D4F-08405FCBFEC1
P2860
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@ast
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@en
type
label
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@ast
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@en
prefLabel
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@ast
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
@en
P2093
P2860
P356
P1433
P1476
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease
@en
P2093
Adam M Weidner
Dana M Niedowicz
Harry LeVine
Irfan Baig
M Paul Murphy
Marta S Mendiondo
Richard J Kryscio
Sergey Matveev
Tina L Beckett
P2860
P304
P356
10.1002/ANA.23633
P50
P577
2012-10-01T00:00:00Z